Published in J Clin Oncol on June 01, 2003
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol (2014) 2.45
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol (2016) 1.83
Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun (2007) 1.59
Breast Cancer 2012 - New Aspects. Geburtshilfe Frauenheilkd (2012) 1.45
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res (2014) 1.23
Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res (2012) 1.19
Multiple treatment comparison meta-analyses: a step forward into complexity. Clin Epidemiol (2011) 1.16
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer (2013) 1.11
Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas (2011) 1.11
Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res Treat (2007) 1.06
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. J Clin Oncol (2015) 1.05
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer (2013) 1.05
The discovery and mechanism of action of letrozole. Breast Cancer Res Treat (2007) 1.04
Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res (2004) 1.01
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res (2008) 1.01
First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? Br J Cancer (2004) 0.97
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. Br J Cancer (2009) 0.95
A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma. Int J Mol Sci (2013) 0.95
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann Oncol (2014) 0.94
Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer (2004) 0.91
Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities. J Med Chem (2013) 0.91
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol (2009) 0.91
Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000. BMC Cancer (2011) 0.90
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer. Breast Cancer (Dove Med Press) (2016) 0.87
Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer (2009) 0.87
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus. Ther Clin Risk Manag (2013) 0.87
Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy. J Cancer Res Clin Oncol (2005) 0.86
Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manag (2008) 0.86
Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. Springerplus (2014) 0.85
Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer. Clin Cancer Res (2014) 0.85
Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer. Breast Care (Basel) (2008) 0.85
Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant. J Steroid Biochem Mol Biol (2006) 0.84
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Med (2015) 0.84
Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res (2015) 0.84
Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat (2007) 0.83
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer. BMC Cancer (2009) 0.83
Breast cancer (metastatic). BMJ Clin Evid (2007) 0.82
Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clin Med Ther (2009) 0.82
Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. Onco Targets Ther (2015) 0.82
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer (2006) 0.82
Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada. Curr Oncol (2013) 0.82
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol (2004) 0.81
The molecular genetics of breast cancer and targeted therapy. Biologics (2007) 0.81
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget (2014) 0.81
Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer. PLoS One (2013) 0.80
Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol (2007) 0.80
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res Treat (2007) 0.80
Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro simulation model. Springerplus (2013) 0.80
Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res (2004) 0.80
Activating ESR1 Mutations Differentially Impact the Efficacy of ER Antagonists. Cancer Discov (2016) 0.80
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer. Breast Cancer (Dove Med Press) (2011) 0.79
Clinical utility of exemestane in the treatment of breast cancer. Int J Womens Health (2015) 0.79
Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities. J Med Chem (2015) 0.79
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res (2015) 0.79
Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review). Oncol Lett (2013) 0.78
The effect of grape seed extract on estrogen levels of postmenopausal women: a pilot study. J Diet Suppl (2014) 0.78
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. Breast Cancer Res Treat (2013) 0.78
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update. Breast Cancer (Dove Med Press) (2011) 0.78
Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players. Front Oncol (2016) 0.78
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. Support Care Cancer (2003) 0.78
Update on the use of aromatase inhibitors in early-stage breast cancer. Breast Cancer Res (2009) 0.77
Breast cancer (metastatic). BMJ Clin Evid (2010) 0.77
Treatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer. J Adv Pract Oncol (2015) 0.77
The patient experience. Breast Cancer Res Treat (2007) 0.77
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors. J Med Chem (2015) 0.77
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. MedGenMed (2005) 0.76
Regulation of adipose oestrogen output by mechanical stress. Nat Commun (2013) 0.76
Aromatase inhibitor strategies in metastatic breast cancer. Int J Womens Health (2010) 0.76
Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. ChemMedChem (2013) 0.76
CYP1A2 - a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients. BMC Cancer (2016) 0.76
Umpolung Synthesis of Diarylmethylamines via Palladium-Catalyzed Arylation of N-Benzyl Aldimines. Adv Synth Catal (2016) 0.75
High-dose toremifene for fulvestrant-resistant metastatic breast cancer: a report of two cases. Case Rep Oncol (2014) 0.75
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer. Cancer Biol Ther (2015) 0.75
Aromatase inhibitors in advanced breast cancer: there are efficacy differences. Br J Cancer (2005) 0.75
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. Cancer Res Treat (2016) 0.75
Endocrine Treatment - 'Old-Fashioned' Therapy Becoming Redundant in an Era of Molecular Medicine? Breast Care (Basel) (2008) 0.75
Human epidermal growth factor receptor 2 protein expression between primary breast cancer and paired asynchronous local-regional recurrences. Exp Ther Med (2011) 0.75
Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer. Oncologist (2016) 0.75
Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study. Arthritis Care Res (Hoboken) (2012) 0.75
Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. Viszeralmedizin (2015) 0.75
Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials. Oncologist (2010) 0.75
Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer. Indian J Surg Oncol (2010) 0.75
Femara and the future: tailoring treatment and combination therapies with Femara. Breast Cancer Res Treat (2007) 0.75
Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. Breast Cancer (Dove Med Press) (2010) 0.75
Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice. PLoS One (2013) 0.75
Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective. Onco Targets Ther (2016) 0.75
Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. ESMO Open (2016) 0.75
Optimal management of breast cancer in the elderly patient: current perspectives. Clin Interv Aging (2015) 0.75
Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptor-positive metastatic breast cancer - A retrospective pilot analysis and viewpoint. South Asian J Cancer (2017) 0.75
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer (2017) 0.75
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer. Int J Clin Oncol (2015) 0.75
Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects. J Cancer Res Clin Oncol (2006) 0.75
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science (2011) 13.16
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol (2006) 9.16
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Evaluation of the bacterial diversity in the feces of cattle using 16S rDNA bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP). BMC Microbiol (2008) 6.28
Ecological impacts of invasive alien plants: a meta-analysis of their effects on species, communities and ecosystems. Ecol Lett (2011) 5.95
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol (2007) 4.94
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol (2006) 4.87
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 4.81
Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin (2006) 4.73
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol (2011) 4.67
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC Microbiol (2008) 4.30
Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer (2013) 4.24
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol (2013) 4.20
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol (2007) 3.51
De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat Genet (2012) 3.49
Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int (2008) 3.45
Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol (2010) 3.38
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell (2011) 3.00
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol (2013) 2.94
Rac function and regulation during Drosophila development. Nature (2002) 2.89
Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One (2008) 2.87
Bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP) for microbiome studies: bacterial diversity in the ileum of newly weaned Salmonella-infected pigs. Foodborne Pathog Dis (2008) 2.77
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol (2012) 2.76
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol (2011) 2.75
Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell (2012) 2.62
Computational analysis of bacterial RNA-Seq data. Nucleic Acids Res (2013) 2.50
Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev (2005) 2.45
The structural basis of blebbistatin inhibition and specificity for myosin II. Nat Struct Mol Biol (2005) 2.45
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol (2012) 2.44
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol (2013) 2.44
Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction (2007) 2.38
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol (2007) 2.36
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2010) 2.34
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol (2008) 2.24
A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell (2006) 2.20
Trends in breast cancer by race and ethnicity. CA Cancer J Clin (2004) 2.19
Rac GTPases control axon growth, guidance and branching. Nature (2002) 2.14
State of the art in research into the risk of low dose radiation exposure--findings of the fourth MELODI workshop. J Radiol Prot (2013) 2.06
The impact of prevention on reducing the burden of cardiovascular disease. Circulation (2008) 2.05
Crop diversity for yield increase. PLoS One (2009) 2.02
MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int Heart J (2009) 2.01
Novel algorithms and the benefits of comparative validation. Bioinformatics (2013) 1.97
Surgical mammography reporting in a limited resource environment. World J Surg (2010) 1.93
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst (2008) 1.92
Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia. Gastroenterology (2009) 1.89
New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA (2011) 1.88
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 1.88
Activation of toll-like receptor (TLR)2, TLR4, and TLR9 in the mammalian cornea induces MyD88-dependent corneal inflammation. Invest Ophthalmol Vis Sci (2005) 1.88
Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol (2006) 1.85
Prospective evaluation of the sensitivity of physical examination in chest trauma. J Trauma (2002) 1.80
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest (2013) 1.76
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer (2006) 1.75
Electrical coupling between mammalian cones. Curr Biol (2002) 1.72
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer (2005) 1.69
Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. J Gastroenterol Hepatol (2008) 1.67
Assessment of the quality of colonoscopy reports: results from a multicenter consortium. Gastrointest Endosc (2009) 1.64
Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. Antimicrob Agents Chemother (2010) 1.60
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol (2012) 1.55
Development of polydimethylsiloxane substrates with tunable elastic modulus to study cell mechanobiology in muscle and nerve. PLoS One (2012) 1.54
Combining biomarkers to detect disease with application to prostate cancer. Biostatistics (2003) 1.54
Predictive value of simple clinical and laboratory variables for dengue hemorrhagic fever in adults. J Clin Virol (2008) 1.54
Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci U S A (2007) 1.53
Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection. Clin Infect Dis (2009) 1.53
Breast cancer worry and mammography use by women with and without a family history in a population-based sample. Cancer Epidemiol Biomarkers Prev (2003) 1.53
Clinical breast examination: practical recommendations for optimizing performance and reporting. CA Cancer J Clin (2004) 1.52
Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1. J Clin Invest (2012) 1.52
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol (2012) 1.52
Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Clin Gastroenterol Hepatol (2013) 1.52
Rhizobacterial volatile emissions regulate auxin homeostasis and cell expansion in Arabidopsis. Planta (2007) 1.51
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol (2008) 1.47
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). Eur Urol (2012) 1.46
A system-wide intervention to improve HIV testing in the Veterans Health Administration. J Gen Intern Med (2008) 1.46
Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci (2010) 1.45
Evaluation of the bacterial diversity among and within individual venous leg ulcers using bacterial tag-encoded FLX and titanium amplicon pyrosequencing and metagenomic approaches. BMC Microbiol (2009) 1.45
IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J Am Soc Nephrol (2010) 1.44
Automating arm movement training following severe stroke: functional exercises with quantitative feedback in a gravity-reduced environment. IEEE Trans Neural Syst Rehabil Eng (2006) 1.44
Longitudinal Survey of Microbiota in Hospitalized Preterm Very-Low-Birth-Weight Infants. J Pediatr Gastroenterol Nutr (2016) 1.42
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern Emerg Med (2013) 1.41
Primary hepatic lymphoma presenting as fulminant hepatic failure with hyperferritinemia: a case report. J Med Case Rep (2008) 1.41